Based on these findings, we confirmed the therapeutic effects of melatonin in diabetes-accelerated atherosclerosis, at least in part, through reducing SNO-GNAI2-induced deactivation of Hippo-YAP axis (Fig. 8). This evidence concerns the gene GNAI2 and diabetes mellitus.